

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HIS

衍生集團(國際)控股有限公司

Hin Sang Group (International) Holding Co. Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6893)

**APPOINTMENT OF EXECUTIVE DIRECTOR
AND
NON-EXECUTIVE DIRECTOR**

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that the Board has resolved on 28 June 2016 to appoint Dr. Dong Meixian as Executive Director with effect from 4 July 2016.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that the Board has resolved on 28 June 2016 to appoint Mr. Yuen Chi Ping as a Non-Executive Director with effect from 4 July 2016.

APPOINTMENT OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Hin Sang Group (International) Holding Co. Ltd. (the “**Company**”) is pleased to announce that the Board has resolved on 28 June 2016 to appoint Dr. Dong Meixian (“**Dr. Dong**”) as Executive Director of the Company with effect from 4 July 2016.

Dr. Dong, aged 45, has more than 20 years of experience in the pharmaceutical and health industry. She obtained a bachelor’s degree from Beijing University of Chinese Medicine, in July 1994, majoring in traditional Chinese medicine, and awarded with a PhD in Integrated Traditional and Western Preclinical Medicine by Guangzhou University of Chinese Medicine in July 2006. She has served in the National food and Drug Administration Southern Medicine Economic Research Institute and some of the fortune 500 companies, and was responsible for the development of primary health products and technology market. She has worked in various senior positions in the technical departments among companies such as Amway, Procter & Gamble, Pepsi, leading product line layout and participating in making of strategic marketing decision.

Dr. Dong is currently a Chief Health Technology Officer of Guangzhou Fullshare Health Management Limited Company, which is a wholly owned subsidiary of Fullshare Holdings Limited (Stock code 00607) the shares of which are listed on the main board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Fullshare Holdings Limited is a substantial shareholder of the Company.

Dr. Dong has entered into a service contract with the Company, her appointment is for a term of 3 years from 4 July 2016. Dr. Dong is entitled to the service fee of HK\$180,000 per annum, which was determined by the Board with reference to her experience and duties and responsibilities with the Company.

As at the date of this announcement, Dr. Dong does not have any interest within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) in any shares, underlying shares or debentures of the Company and/or its associated corporation.

Dr. Dong has confirmed that there is no information which should be disclosed under Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) nor is/was she involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the Shareholders of the Company in connection with her appointment.

APPOINTMENT OF NON EXECUTIVE DIRECTOR

The Board of the Company is pleased to announce that the Board has resolved on 28 June 2016 to appoint Mr. Yuen Chi Ping (“**Mr. Yuen**”) as a Non-Executive Director of the Company with effect from 4 July 2016.

Mr. Yuen, aged 37, is a qualified lawyer in both Hong Kong, and England and Wales. Mr. Yuen has over 12 years of experience practicing as a lawyer in the PRC and Hong Kong, and has extensive experience in corporate law, China-related public and private mergers and acquisitions, and capital market transactions. Mr. Yuen obtained a bachelor’s degree in Laws in 2001 and completed the PCLL programme in 2002 in the University of Hong Kong, then undertook his traineeship and worked as a lawyer in various leading international law firms. He worked as a special counsel in the Shanghai office of Baker & McKenzie and was responsible for the firm’s securities practice in Shanghai.

Mr. Yuen is currently the head of investment and legal of Fullshare International Group Limited and the Chief Operating Officer of Fullshare Holdings Limited (Stock Code 00607), the shares of which are listed on the Main Board of Stock Exchange. Fullshare Holdings Limited is a substantial shareholder of the Company.

Mr. Yuen has entered into a service contract with the Company, his appointment is for a term of 3 years from 4 July 2016. Mr. Yuen is entitled to the service fee of HK\$180,000 per annum, which was determined by the Board with reference to his experience and duties and responsibilities with the Company.

As at the date of this announcement, Mr. Yuen does not have any interest within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) in any shares, underlying shares or debentures of the Company and/or its associated corporation.

Mr. Yuen has confirmed that there is no information which should be disclosed under Rule 13.51(2)(h) to (v) of the Listing Rules nor is/was he involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the Shareholders of the Company in connection with his appointment.

The Board would like to take this opportunity to welcome Dr. Dong and Mr. Yuen for joining the Board.

By order of the board
Hin Sang Group (International) Holding Co. Ltd.
Pang Siu Hin
Chairman

Hong Kong, 28 June 2016

As at the date of this announcement, the executive directors are Mr. Pang Siu Hin and Ms. Kwan Lai Man, the non-executive director is Ms. Wong Wai Ling, and the independent non-executive directors are Mr. Lee Luk Shiu, Dr. Tang Sing Hing, Kenny and Mr. Tsui Nam Hung.